Degenerative-dystrophic diseases of the joints and spine; primary and secondary osteoarthritis, osteochondrosis, shoulder periarthritis; fractures (to accelerate the formation of bone calluses).
Protecon Composition and form of release
Main active ingredients: chondroitin 400 mg, glucosamine 500 mg.
Auxiliary components are: cellulose, silicon dioxide, talc, sodium croscarmellose, hypromellose, titanium dioxide, tartrazine, etc.
Produced in tablet form.
The specified drug Protecon is included in the group of non-steroidal anti-inflammatory and anti-rheumatic drugs that are used for diseases of the joints and spine.
One of the main active ingredients, chondroitin, is a polymeric sulfated glycosaminoglycan. It is an integral part of the articular synovial fluid secreted by the cartilage tissue of the joint. Able to suppress the activity of enzymes that cause disruption of the integrity of cartilage tissue.
Chondroitin, as well as its constituent glucosamine, has the property of influencing the metabolic chemical processes occurring in the cartilage tissue, in which calcium and phosphorus participate. It is able to inhibit the process of resorption of bone tissue, prevents the development of seals of connective tissues. It is a lubricant for the joint surface.
Chondroitin also has the ability to normalize the production of joint fluid, to take part in the reproduction of the basic substances of bone tissue, as well as cartilage tissue. As a result, when using this drug, joint mobility improves, the development of osteoarthritis slows down.
At the same time, the inflammatory process decreases and pain in the joints affected by the disease decreases.
Used to treat degenerative-dystrophic diseases of the joints and spine. In particular, when treating:
- osteoarthritis, osteochondrosis;
- primary arthrosis, intervertebral osteochondrosis;
- osteoporosis, periodontal disease;
- fractures, treatment of the consequences of surgical interventions on the joints.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Contraindicated for use when:
- thrombophlebitis (inflammation of the vascular wall, accompanied by the formation of a blood clot);
- bleeding tendency;
- renal failure;
- diabetes mellitus.
Not used in pediatrics.
Application during pregnancy and lactation
This drug is contraindicated for use in the treatment of pregnant women.
If it is necessary to administer the drug during breastfeeding, then lactation should be suspended for the duration of treatment.
Method of administration and dosage
The drug Protecon is administered orally (inside).
- the first 3 weeks – 1 tablet 3 times a day;
- starting from the 4th week – 1 tablet 2 times a day.
The duration of the treatment course is determined individually, depending on the effectiveness and tolerability of therapy. Usually, the average treatment course is 60-90 days. Treatment courses can be repeated 2-3 times a year.
The recommended doses should not be exceeded and the duration of the recommended treatment should not be exceeded.
There have been no reports of an overdose of this drug. In theory, hypersensitivity reactions may increase.
In this case, you should stop using the drug and consult a doctor to change the appointment.
The drug is generally well tolerated and rarely causes side effects, being recognized for its safety and easy absorption.
In some cases, hypersensitivity reactions may occur. In particular, manifestations are possible:
- itching, redness, erythema, dermatitis, alopecia;
- rash, allergic urticaria;
- anaphylactic shock, angioedema;
- nausea, vomiting, abdominal pain, flatulence, dyspeptic symptoms;
- disorders of the organs of vision, keratopathy, dizziness, peripheral edema, weakness.
Storage conditions and periods Protecon
The shelf life is up to 3 years.
Storage temperature – no higher than 25 ° С.